Search Results
Your search for ,maY matches 16485 pages
Showing 5151 - 5200Umbralisib for Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, and colleagues, the phase IIb UNITY-NHL trial has shown that the dual PI3Kδ/casein kinase (CK) 1ε inhibitor umbralisib produced durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma. The study ...
Using CT Colonography as a Noninvasive Colorectal Cancer Screening Test for Advanced Neoplasia
According to a report published by Pickhardt et al in the American Journal of Roentgenology (AJR), compared with multitarget stool DNA and fecal immunochemical tests, computed tomography (CT) colonography using a polyp size threshold ≥ 10 mm most effectively targeted advanced neoplasia—preserving...
Can Treatment for Prostate Cancer Affect Smell and Taste?
One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al in the journal Supportive Care in Cancer. The study authors noted that a reduced sense of smell and taste among some patients with...
Updated Evidence Report and Systematic Review of Low-Dose CT Screening for Lung Cancer
In an analysis of updated evidence on low-dose computed tomography (CT) screening for lung cancer reported in JAMA, Jonas et al found that screening can reduce lung cancer mortality but may be associated with a range of potential harms. The analysis was performed to inform the new U.S. Preventive...
High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology. The findings suggest that TMB status may not be reliably used as a universal...
Study Identifies Factors That May Lower the Risk of CNS Relapse in Pediatric Patients With ALL
Starting chemotherapy several days before the first lumbar puncture for diagnosis and treatment of acute lymphoblastic leukemia (ALL) may reduce the risk of central nervous system (CNS) relapse in children, according to a study published by Tang et al in the journal Blood. The research focused on...
Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?
Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...
Novel HER2-Targeted Therapies Pose Sequencing Challenges
With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and Drug ...
Lowering KRAS Activity May Lead to Improved Therapy Response in Pancreatic Cancer
If clinicians could stop mutations of the KRAS gene—which are present in more than 90% of pancreatic cancer cases and drastically reduce the response to immunotherapy—the chances of improving treatment for the disease would be increased. A collaborative study published by Ischenko et al in Nature...
CheckMate 9ER: First-Line Nivolumab Plus Cabozantinib vs Sunitinib for Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and overall survival vs sunitinib in first-line treatment of patients with...
Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality
New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...
Expect Questions From Older Breast Cancer Survivors About Discontinuing Routine Surveillance Mammography
Consensus guidelines recommending that routine surveillance mammography be discontinued for older breast cancer survivors with a limited life expectancy1 may raise questions among patients concerned about undetected cancer recurrence. Informing older survivors about the new recommendations and the...
Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy
Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...
International Perspectives on Integrative Medicine for Cancer Prevention and Management
Guest Editor’s Note: Although many cancer centers recognize the value of integrative therapies in oncologic care, cancer prevention, its treatment, and survivorship care continue to pose a challenge in many low- and middle-income countries. In this article, Alejandro Salicrup, PhD, highlights the...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Weight Gain in Childhood Brain Tumor Survivors and Potential Association With Hypothalamic-Pituitary Dysfunction
In a Dutch study reported in the Journal of Clinical Oncology, van Schaik et al found that significant weight gain and being overweight and/or obese are common in childhood brain tumor survivors and may be associated with hypothalamic-pituitary dysfunction. Study Details The study involved data...
Repurposing Available Drugs for COVID-19: An Ongoing Initiative
As of this writing, no drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19, although several have received emergency use authorization and many others are being used off-label during the pandemic. In addition to searching for novel therapies, David...
New Study Finds Muscle Mass and Density Are Correlated With Survival and Outcomes in Patients With Advanced Cancer
New research published by van Seventer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that muscle mass was correlated with survival, while muscle radiodensity was associated with symptom burden, health-care use, and survival in patients with advanced cancer undergoing ...
ASCO Guideline Update Offers Four Standards of Care for Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
A recent ASCO guideline update, prompted by data from several phase III randomized controlled trials, summarizes the evidence supporting the best initial treatment options for the management of noncastrate advanced, recurrent, or metastatic prostate cancer. The hope is that the guideline will help...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD
The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...
Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint
Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Oncologist Survey Identifies Knowledge Gaps in Cholangiocarcinoma Mutations
In the treatment of cholangiocarcinoma, many clinicians may be unaware of the importance of the major oncogenic mutations and other alterations that can be identified and targeted, according to a survey of oncologists presented at the 2021 Gastrointestinal Cancers Symposium.1 “Recent developments...
Fallout From COVID-19: Decline in Cancer Screening and Increase in Cancer-Related Deaths
Various studies at institutions in the United States and abroad have shown a substantial decline in cancer screening rates during the COVID-19 pandemic, suggesting that fewer cancers will be detected by screening and when they do manifest, they will be at more advanced stages. Indeed,...
Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD
“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...
Kratom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on...
Expert Point of View: Frank Keller, MD, and E. Anders Kolb, MD
Frank Keller, MD, a pediatric hematologist/oncologist with Children’s Healthcare of Atlanta–Egleston Hospital, and E. Anders Kolb, MD, Director of the Nemours Center for Cancer and Blood Disorders, Nemours Children’s Health System in Delaware, provided comments on the studies for The ASCO Post....
Studies Provide Guidance on the Use of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia
Monotherapy with blinatumomab as consolidation therapy before allogeneic stem cell transplant appears to be the optimal treatment for children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (ALL), according to an international phase III trial that compared this approach...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 3, 2021, tepotinib was granted accelerated approval for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1,2 Supporting Efficacy Data Approval was supported by findings from the...
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
Continued Survival Benefit With Durvalumab Plus Chemotherapy vs Chemotherapy Alone in Extensive-Stage SCLC
As reported in The Lancet Oncology by Jonathan W. Goldman, MD, of the David Geffen School of Medicine at University of California Los Angeles, and colleagues, updated results from the phase III CASPIAN trial show maintained improvement in overall survival with first-line durvalumab plus...
Atezolizumab’s Indication in Previously Treated Metastatic Bladder Cancer Is Withdrawn
Genentech, a member of the Roche Group, announced on March 8 that the company is voluntarily withdrawing the U.S. indication for atezolizumab (Tecentriq) in patients with prior platinum-treated metastatic urothelial carcinoma. This decision was made in consultation with the U.S. Food and Drug...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
Study Reports Little Benefit to Adding Pembrolizumab to Neoadjuvant Therapy for Locally Advanced Rectal Cancer
The addition of pembrolizumab to neoadjuvant chemotherapy and radiotherapy (ie, total neoadjuvant therapy) failed to improve a rectal cancer–specific surrogate for survival in patients with locally advanced disease in the phase II NRG-GI002 trial.1 As reported at the 2021 Gastrointestinal Cancers...
David Fajgenbaum, MD, MBA, on Repurposing Cancer Drugs to Treat COVID-19
David Fajgenbaum, MD, MBA, of the University of Pennsylvania, talks about his research efforts to find an already-approved drug that could treat his orphan disease—multicentric Castleman disease—and how that methodology may be applied to the coronavirus and the cytokine storm it can cause...
New WHO/IAEA Publication Provides Guidance on Radiotherapy Equipment Procurement
New guidance from the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA) on the procurement of radiotherapy equipment could improve access to this life-saving cancer treatment option across the world. The new technical guidance aims to ensure that the selection of...
Salpingo-Oophorectomy to Reduce Ovarian Cancer Risk in Women With BRCA1 or BRCA2 Pathogenic Variants May Also Reduce Breast Cancer Risk
In a study reported in JAMA Oncology, Choi et al found that risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 pathogenic variants was associated with a reduced risk of breast cancer within 5 years after surgery, with evidence of longer-term risk reduction among those with BRCA1...
Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic
A new report from Italy published by Toss et al in ESMO Open noted an increase in diagnoses of node-positive and stage III breast cancer after a 2-month interruption in breast cancer screening due to the COVID-19 pandemic. These findings support recommendations for a quick restoration of breast...
Role of Collagen in Pancreatic Cancer Development
Type I collagen produced by cancer-associated fibroblasts may not promote cancer development, but instead, may play a protective role in controlling pancreatic cancer progression. This new understanding supports novel therapeutic approaches that bolster collagen rather than suppress it, according...
Study Finds Cancer Survivors With Poor Ambulatory Function May Be at an Increased Risk of Death
A study by Salerno et al published in Cancer Epidemiology, Biomarkers & Prevention investigating the association of a cancer diagnosis and poor ambulatory function of survivors and subsequent mortality has found that cancer survivors with poor ambulatory function had a two to three times...
Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma
Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...
Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality
In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...
Long-Term Follow-up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors
Final analysis of a collaborative intergroup study confirmed the efficacy of adjuvant treatment with imatinib in patients with localized gastrointestinal stromal tumor (GIST) in terms of prolonged relapse-free survival. In the high-risk subgroup, there was a trend toward a better long-term imatinib ...
Preclinical Research Shows Activity of Fidaxomicin Combination Therapy in MLL-AML
A specific type of acute myeloid leukemia (AML) that contains a rearrangement in the MLL gene (also known as KMT2A) might be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhea, according to new research published by Zeisig et al in Science Translational...
Recent Study Examines Potential New Therapies, Assessment of Biomarkers in Endometrial Cancer
In a new study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention, researchers demonstrated that sex hormones and insulin growth factors may be associated with recurrence risk in patients with endometrial cancer. The findings suggest endocrine-targeted therapies and an...
Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II TRANSFORMER trial reported in the Journal of Clinical Oncology, Denmeade et al found no difference in progression-free survival with bipolar androgen therapy—defined as rapid cycling between high and low serum testosterone—vs enzalutamide in men with metastatic castration-resistant...
Five-Year Outcomes With Tisagenlecleucel in Patients With Relapsed or Refractory B-Cell Lymphomas
As reported in a letter to the editor in The New England Journal of Medicine by Elise A. Chong, MD, and colleagues, long-term follow-up of a single-center trial of tisagenlecleucel showed maintained responses in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ...
Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn
On March 1, Merck announced the company is voluntarily withdrawing the U.S. indication for pembrolizumab (Keytruda) for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The ...
Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma
Patients with lymphoma hospitalized for severe COVID-19 infection were at higher risk for prolonged hospital stay and death if they were treated with B-cell–depleting therapies (eg, rituximab, obinutuzumab) within the previous 12 months. The risk of persistent COVID-19 infection was also higher in...
